NovoCure Ltd
Tremor tracks 6 of its cancer trials.
Company-wide warning signs
These add points to every one of this company's trials.
- 8 insiders sold shares within a monthSince Jun 4, 2026+1.7
Trials
- NVCRNovoCure GmbH12Calm
Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC).
FinishedPhase 3298 patientsMain results: Nov 29, 2024 - NVCRNovoCure GmbH2Calm
EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma
Running, no new patientsPhase 3741 patientsMain results: Apr 2029 - NVCRNovoCure GmbH2Calm
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
Signing up patientsPhase 3734 patientsMain results: Oct 2028 - NVCRNovoCure Ltd.2Calm
EF-39 PANOVA-4: Study of Tumor Treating Fields Concomitant With Atezolizumab, Gemcitabine and Nab-Paclitaxel as First-LineTreatment for Metastatic Pancreatic Ductal Adenocarcinoma
FinishedPhase 284 patientsMain results: Nov 18, 2025 - NVCRNovoCure GmbH2Calm
Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR)
FinishedPhase 3291 patientsMain results: Sep 24, 2024 - NVCRNovoCure Ltd.2Calm
Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel (PANOVA-3)
FinishedPhase 3571 patientsMain results: Oct 16, 2024
Key executives leaving
From the last 12 months of the company's SEC reports.
Insider trades (last 6 months)
“Insiders” are executives, board members, and big shareholders. Many of their sales are pre-planned: scheduled months ahead under a legal plan (called 10b5-1), so they usually say little. Tremor only counts sales that weren't pre-planned.
9 sales (9 not pre-planned) · 0 purchases
- Puri Michal NathChief Human Resources Officer · Nov 2, 2026Sold 660 sharesabout $9 thousand · not pre-planned
- Leonard Frank XChief Executive Officer · Jun 4, 2026Sold 34,273 sharesabout $615 thousand · not pre-planned
- LEUNG GABRIELBoard member · Jun 2, 2026Sold 2,945 sharesabout $46 thousand · not pre-planned
- Stafford KristinBoard member · Jun 2, 2026Sold 2,945 sharesabout $46 thousand · not pre-planned
- Ocean Allyson JBoard member · Jun 2, 2026Sold 2,945 sharesabout $46 thousand · not pre-planned
- Scannell Timothy JBoard member · Jun 2, 2026
Recent SEC filings
Public companies must report important news and their finances to the SEC, the US agency that oversees the stock market.